BRIEF—WuXi AppTec and Ark Biosciences to work together

WuXi AppTec subsidiary STA Pharmaceutical has agreed terms with fellow Chinese firm Ark Biosciences for a strategic partnership for Chemistry, Manufacturing, and Controls (CMC) development and manufacturing.

WuXi STA will focus on R&D and manufacturing, while Ark Biosciences will “utilize the Marketing Authorization Holder (MAH) scheme to accelerate drug development.”

Ark chief executive Jim Wu said: “We’re delighted to partner with such a well-respected, world-class CDMO such as WuXi STA. WuXi STA’s enabling end-to-end CMC platform, scale, and innovation capabilities will help us to move our drug candidates from the clinical-stage to commercialization more efficiently.”